RGBP posted a flat QoQ revenue run rate of 59,065 in QQ2 2024 with a robust gross margin of approximately 70.9%, but the quarter shows a deep operating loss driven by heavy non-cash depreciation and high overhead. Net income declined to -122,473, with EBITDA of -101,070 and a negative operating margin of -1.71%. Cash flow remained deeply negative from operations, at -209,321, leading to a closing cash balance of roughly 78,114, while financing activities provided a modest inflow of 162,937 to support liquidity. The balance sheet remains structurally levered, with total liabilities far exceeding assets and a negative stockholders’ equity position. The company’s deferred revenue of 1.53 million signals advance commitments offset against ongoing burn, underscoring an acute need for additional financing or strategic partnerships to extend the runway. In the near term, RGBP’s investment appeal hinges on downstream catalysts such as progress in NR2F6-based programs, potential licensing collaborations, or transformative equity financing. Given the current data, RGBP remains a high-risk, high-reward speculative name within Healthcare/Biotechnology.